Matching placebo to glimepiride

DRUG2 trials

Sponsors

Merck Sharp & Dohme LLC

Conditions

Type 2 Diabetes Mellitus

Phase 3

A Study to Evaluate the Safety, Tolerability, and Efficacy of the Addition of Omarigliptin (MK-3102) to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Therapy (MK-3102-024)

CompletedNCT01755156

Merck Sharp & Dohme LLCType 2 Diabetes Mellitus

Start: 2013-01-11End: 2016-03-16Updated: 2018-09-10

Phase 4

Efficacy and Safety of Sitagliptin/Metformin Fixed-Dose Combination (FDC) Compared to Glimepiride in Participants With Type 2 Diabetes Mellitus (MK-0431A-202)

CompletedNCT00993187

Merck Sharp & Dohme LLCType 2 Diabetes Mellitus

Start: 2010-05-04End: 2013-10-29Updated: 2018-08-22